Purolite celebrates expansion of innovative bioprocessing facility in Wales
Purolite, an Ecolab company, marked the opening of a new Customer Experience Centre featuring hands-on interactive and educational displays, showcasing the company’s expanded bioprocessing solutions.
Ecolab company Purolite held its ribbon-cutting ceremony on October 13 in celebration of their manufacturing expansion, which will see production capacity triple for the company’s bioprocessing resin production to meet global demands. In an interview with Chris Major, General Manager of the Bioprocessing division, Purolite’s expanded features will also bring attention to its commitment to the environmental impact of manufacturers.
L-R: Chris Major, Hayley Crowe, His Majesty's Lord-Lieutenant of Mid Glamorgan Peter Vaughan
The expansion includes a newly opened Customer Experience Centre featuring hands-on interactive and touch-screen educational displays showcasing Purolite’s bioprocessing solutions. As part of a multimillion-dollar global investment from Ecolab, increased office space, training areas, and conference room facilities will also be on offer.
Major stated: “It creates a space where our team can be really creative. When you’ve got some of the brightest minds in the industry, you want to have a nice place for them to work – you want to have a place where they feel inspired and where they can think about the next-generation products that are going to help impact the next generation of therapeutics, that’s what the innovation centre does. It creates an environment for our people to be free-thinking and innovative.”
Major emphasized Purolite’s continued commitment to bringing their customers sustainable processes and an ethical environment for their manufacturing needs. As a modular-built facility with 27 Portacabins, each cabin boasts the usage of second-use recycled steel. Groundwater heat pumps utilise thermal energy, which can be converted to use as renewable energy throughout the facility. Solar panels run the facility at close to net-zero energy. However Major noted that such facility features are only a small part of Purolite’s commitment to sustainability.
L-R: Hayley Crowe, Chris Major, Gergely Sved
“The big advantage that we have is the technology we have developed. For the last 50 years, there’s really been one method of manufacturing the type of technology that we do, and it has remained virtually unchanged since the 1950s. Over the last five to seven years, we’ve worked to revolutionise this type of a manufacturing method to something we’ve patented called ‘jetting method’. Jetting technology allows us to precisely control size to make uniform beads... By the way that we’ve designed and implemented this manufacturing technology, we’ve been able to substantially reduce the amount of water (compared to the traditional manufacturing method).” In addition to reducing water usage and wastage, Major also stated that carbon dioxide emissions were significantly reduced with the patented jetting method, as well as almost eliminating harmful solvents. With sustainable manufacturing methods, Major highlights that Purolite not only reduces their own environmental impact but also that of their customers who choose to partner with them.
The expanded facility in Wales runs in parallel to construction at Purolite’s facility in the United States, giving Purolite a dual-continent capability to make innovative therapeutics around the world accessible. Major emphasized that a pillar of Purolite’s ethos is not only to develop and manufacture exciting new technologies in support of biopharmaceuticals, but to also make healthcare an accessible right across the globe.
Major concluded with a highlight of some of Purolite’s business achievements, including a series of global awards and recognitions. Purolite UK was awarded the Queen's Award for Enterprise in 2022, given by His Majesty’s Lord Lieutenant of Mid Glamorgan. With a wider global footprint, Purolite’s headcount has almost doubled, something Major anticipates will only increase in the coming years. The Wales Business Award for Most Innovative Company was also presented to Purolite, further demonstrating Purolite’s commitment and production of cutting-edge technology.
Read more about Purolite’s expansion here.
Related News
-
News Women in Pharma: Moving beyond discussions and into best practice at CPHI Milan
In this second CPHI Milan special of our monthly series, we cover the key takeaways from the Diversity & Wellbeing track held on October 10, 2024. -
News AstraZeneca invests in AI collaboration for cancer drug trials
The British-Swedish pharmaceutical giant is partnering with biotechnology firm Immunai Inc to increase the efficiency of some cancer drug trials. -
News Ozempic and Wegovy prices questioned as Novo Nordisk faces US Senate hearing
The CEO of Novo Nordisk was grilled during a US Senate committee hearing on September 24, 2024, in which the exorbitant prices of the Danish company’s blockbuster drugs Ozempic and Wegovy were called into question. -
News The BIOSECURE Act: implications for the pharma supply chain
On September 9, 2024, the US House of Representatives voted to pass the bill titled the BIOSECURE Act (the Act), which lists several Chinese companies in the pharmaceutical supply chain. The Act will prohibit American companies from contracting or doin... -
News On Track at CPHI Milan: Thermo Fisher Scientific Track Sponsor interview
With CPHI Milan just around the corner, we sat down with some of the sponsors for this year’s conference tracks to discuss the most pressing topics in pharma. -
News CPHI Milan Speaker Spotlight: Pharma Manufacturing and Localisation in Africa
In the run-up to CPHI Milan, we sit down with some of the experts and thought-leaders speaking at this year’s conferences. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Eli Lilly licenses rheumatoid arthritis manufacturing in Africa
American pharmaceutical company Eli Lilly has signed a partnership with Egyptian organisation Eva Pharma to localise manufacturing of rheumatoid arthritis treatments in Africa.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance